Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
Background Cancer anorexia-cachexia syndrome is associated with increased morbidity and mortality. Anamorelin is an oral ghrelin-receptor agonist with appetite-enhancing and anabolic activity. We assessed the effects of anamorelin on body composition, strength, quality of life, biochemical markers, and safety in patients with cancer anorexia-cachexia.Methods Data were pooled, a priori, from two completed phase 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurable cancer and weight loss of 5% or more. Patients were stratified by weight loss severity (5-15%, >15%) and randomly allocated (1:1) with a computer-generated randomisation schedule to anamorelin hydrochloride 50 mg or placebo once-daily for 12 weeks. Primary outcome was lean body mass by dual-energy x-ray absorptiometry over the 12 week treatment period in eligible patients who had at least one dose of study drug and post-treatment efficacy assessment. We assessed safety in all patients who received at least one dose of study drug. The trials are registered with ClinicalTrials.gov, numbers NCT00219817 and NCT00267358.Findings Between June 29, 2005, and Oct 26, 2006, we enrolled 44 patients in the anamorelin group and 38 patients in the placebo group. 74 patients were eligible for the efficacy analyses. Over 12 weeks, lean body mass increased in 38 patients in the anamorelin group by a least-squares mean of 1.89 kg (95% CI 0.84 to 2.95) compared with a decrease of a least-squares mean of -0.20 kg (-1.23 to 0.83) for 36 patients in the placebo group (difference 2.09 kg [0.94-3.25]; p=0.0006). 42 (95%) of 44 patients treated with anamorelin and 33 (87%) of 38 patients treated with placebo had adverse events. The most common grade 3-4 adverse events (treatment-related or not) in the anamorelin group were fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] each); in the placebo group, such events were pneumonia (three [8%]) and anaemia, thrombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each).Interpretation Anamorelin treatment for 12 weeks had a favourable clinical response profile in patients with cancer anorexia-cachexia syndrome. These findings support further investigation in this setting.Funding Helsinn Therapeutics (US), Helsinn Healthcare SA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anamorelin improved lean mass in patients with cancer cachexia compared with placebo (2.09 kg, 95% CI 0.94–3.25; P = 0.0006)440 but failed to improve muscle power or handgrip strength in patients with inoperable nonsmall-cell lung cancer441.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [440]
In the citing paper
“Ghrelin receptor agonists like anamorelin increase lean mass and stimulate appetite in cancer cachexia [72], but appetite stimulation may be counterproductive alongside GLP-1-mediated appetite suppression.”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [72]
In the citing paper
“Consistently, anamorelin, an oral ghrelin-receptor agonist, elicits an anabolic action in patients with cancer anorexia–cachexia syndrome96.”
From Mechanisms of muscle atrophy and hypertrophy: implications in health and disease (2021) · cites this paper as [96]
Citations
Cites
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Grip strength, body composition, and mortality
Gale, C. R., Martyn, C. N., Cooper, C., & Sayer, A. A. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dyl224 · Cited by 737
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia
Das, S. K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., Gorkiewicz, G., Tamilarasan, K. P., Kumari, P., Trauner, M., et al. (2011) · Science · doi:10.1126/science.1198973 · Cited by 581
Cachexia as a major underestimated and unmet medical need: facts and numbers
von Haehling, S., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0002-6 · Cited by 533
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Ross, P. J., Ashley, S., Norton, A., Priest, K., Waters, J. S., Eisen, T., Smith, I. E., & O'Brien, M. E. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601781 · Cited by 476
Aapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S. M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu085 · Cited by 308
Megestrol acetate for treatment of anorexia-cachexia syndrome
Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., Gonzalvez Perales, J. L., & Bort-Martí, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004310.pub3 · Cited by 293
Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-9-200811040-00003 · Cited by 255
Kilgour, R. D., Vigano, A., Trutschnigg, B., Lucar, E., Borod, M., & Morais, J. A. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1894-4 · Cited by 255
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130
Mechanisms of muscle atrophy and hypertrophy: implications in health and disease
Sartori, R., Romanello, V., & Sandri, M. (2021) · Nature Communications · doi:10.1038/s41467-020-20123-1 · Cited by 940
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Self-citationUnderstanding cachexia as a cancer metabolism syndrome
Porporato, P. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.3 · Cited by 562
Metadata
- Authors
- Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Georgetown University (US)
- Helsinn Therapeutics (United States) (US)
- Corresponding author
- Garcia, José M
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 16
- Issue
- 1
- Pages
- 108-116
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W1987892987
- Cited by
- 218
- References
- 38
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 17 · 2022: 8 · 2021: 19 · 2020: 14 · 2019: 21 · 2018: 23 · 2017: 30 · 2016: 28 · 2015: 17
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Helsinn
- Helsinn Therapeutics
- National Institute on Aging (R03AG040583, AG040583, NIA T32AG000183, T32AG000183)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Keywords
- anamorelin, cancer cachexia, anorexia-cachexia syndrome, ghrelin receptor agonist, lean body mass, body composition, weight loss, advanced cancer, appetite, quality of life, muscle strength, adverse events, atrial fibrillation, fatigue, drug safety, pooled analysis of trials, anabolic activity
- MeSH terms
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Body Composition, Cachexia, Female, Humans, Hydrazines, Male, Middle Aged, Neoplasms, Oligopeptides, Quality of Life, Time Factors, United States, Weight Gain, Absorptiometry, Photon, Least-Squares Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Appetite Stimulants, Anabolic Agents, Muscle Strength, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71154-4
- The paper
- Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71154-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.